Lumenis Announces New Clinical Evidence for BPH Using its Patent-Protected MOSES™ Technology

Lumenis Announces New Clinical Evidence for BPH Using its Patent-Protected MOSES™ Technology

New clinical evidence of the advantages of lithotripsy treatment of benign prostatic hyperplasia (BPH) using MOSES™ Technology is being presented at the American Urological Association's (AUA) annual meeting, taking place in Chicago, May 3-6, 2019.

TerraLab Ventures want to make Yokneam a hub for all of northern Israel, not just a bridge between Israel’s center and the North

TerraLab Ventures want to make Yokneam a hub for all of northern Israel, not just a bridge between Israel’s center and the North

Terra Venture Partners, established almost a decade ago as a cleantech investment fund, invests in companies from a range of industries with a positive impact on society, including in agriculture, construction, manufacturing, transportation and healthcare.

ReWalk Robotics Completes One-for-Twenty-Five Reverse Share Split

ReWalk Robotics Completes One-for-Twenty-Five Reverse Share Split

The reverse split will take effect tomorrow, April 1. As a result of the reverse share split, every twenty-five ordinary shares of ReWalk issued and outstanding were automatically combined and reclassified into one ordinary share of ReWalk. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.

Nvidia acquires Mellanox for $6.9 Billion

Nvidia acquires Mellanox for $6.9 Billion

NVIDIA and Mellanox just announced that NVIDIA has agreed to a cash purchase of all issued and outstanding common stock at a price of $125/share.

10-minute-treatment developed in Yokneam reduces prostate gland without surgery

10-minute-treatment developed in Yokneam reduces prostate gland without surgery

The treatment is given with a device small butterfly-shaped stent, which lifts the prostate's lobes and supports them so that they do not squeeze the urethra and cause it to narrow. The device, developed by Butterfly Medical, does not meet the urinary fluid and therefore does not expose patients to the risk of infection and stones. The patients who received the treatment reported that they did not feel the implant and did not experience any pain.